Insights
The evidence behind the vial
This is where our research write-ups, study breakdowns and practical guides live, so you can check the reasoning before you buy.
Tirzepatide and retatrutide: what the trials show
Two of the biggest numbers in obesity research came out of the same lab. Here is how the phase trials compare, and what the figures actually mean.
02 Jul 2026 / 1 min read
GHK-Cu for skin and hair, sorting the good data from the thin
The topical GHK-Cu skin data includes several small randomised trials with real measured endpoints, which puts it ahead of most cosmetic peptides. The hair claims rest on considerably less.
13 Jul 2026 / 4 min read
How to reconstitute a peptide vial without wasting it
Lyophilised peptides are fragile in ways that are easy to miss. A short guide to mixing, storing and dosing without degrading what you paid for.
10 Jul 2026 / 1 min read
Tirzepatide and retatrutide: what the trials show
Two of the biggest numbers in obesity research came out of the same lab. Here is how the phase trials compare, and what the figures actually mean.
02 Jul 2026 / 1 min read
Peptide storage, the cold chain and what degrades your vial
Lyophilised peptide is far more forgiving than most people assume, and reconstituted peptide is far less. The practical rules for fridge, freezer, freeze-thaw and getting a vial through an airport.
26 Jun 2026 / 5 min read
What the research actually says about BPC-157
BPC-157 is the most talked-about recovery peptide on the market. Here is what the published work supports, and where the evidence runs out.
18 Jun 2026 / 1 min read
Nasal spray, injection or pen and what bioavailability costs you
A peptide that is 90 percent bioavailable subcutaneously and 2 percent intranasally is not the same product at the same label dose. Here is how the three delivery routes compare and what the numbers mean for what reaches your blood.
11 Jun 2026 / 5 min read
How much of GLP-1 weight loss is muscle
Body composition substudies from the semaglutide and tirzepatide trials put lean mass loss at roughly 25 to 40 percent of total weight lost. What that figure means depends heavily on what it is being compared to.
27 May 2026 / 4 min read
CJC-1295, Ipamorelin and Tesamorelin compared
The three most common growth hormone secretagogues work through different receptors and produce very different release patterns. Understanding pulsatility explains why timing matters and why IGF-1 is the number you should be tracking.
08 May 2026 / 5 min read
How to read a certificate of analysis without being fooled
Most peptide COAs in circulation are either incomplete, unreadable, or copied from another batch. This walks through what each test on the page tells you and the specific things that mark a document as worthless.
24 Apr 2026 / 5 min read
What the TB-500 repair evidence shows
Thymosin beta-4 has a genuine mechanism and decent animal data for wound and tendon repair, but the human trials that ran were small, mixed, and mostly about eyes and skin. Here is where the evidence holds and where it runs out.
14 Apr 2026 / 4 min read